| (+)-Erinacin A |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| (+)-Mcl-1 inhibitor 21 |
|
|
|
|
|
|
|
|
|
|
|
|
| (+)-Mcl-1 inhibitor 22 |
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Clerosterol |
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Mcl-1 inhibitor 21 |
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Mcl-1 inhibitor 22 |
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Norgestrel-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-β-Peltatin |
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| (-)-Syringaresinol |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| (-)BI97D6 |
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-[8]-Shogaol |
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-Mcl-1 inhibitor 7 |
|
|
|
|
|
|
|
|
|
|
|
|
| (E/Z)-CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-(-)-Gossypol |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| (R)-(-)-Gossypol acetic acid |
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| (R)-MIK665 |
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-Sulforaphane |
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| (R,R)-S63845 |
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| (Rac)-BDA-366 |
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-HA14-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-Lisaftoclax |
|
|
|
|
|
|
|
|
|
|
|
98.22% |
| (S)-Sabutoclax |
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| (S)-Gossypol (acetic acid) |
|
|
|
|
|
|
|
|
|
|
|
98.46% |
| (S,R)-S63845 |
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| 15(S)-HPETE |
|
|
|
|
|
|
|
|
|
|
|
97.32% |
| 155H1 |
|
|
|
|
|
|
|
|
|
|
|
|
| 17-Hydroxy sprengerinin C |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| 2,5-Hexanedione-d10 |
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| 2-Hydroxychalcone |
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| 2-Methoxyjuglone |
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Tetralone |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| 23-Hydroxybetulinic acid |
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Alisol A 24-acetate |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 3′,4′,7-Trihydroxyflavone |
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| 3′,6-Disinapoylsucrose |
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| Hexamethylquercetagetin |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 3-Tridecylphenol |
|
|
|
|
|
|
|
|
|
|
|
|
| 4′-Hydroxywogonin |
|
|
|
|
|
|
|
|
|
|
|
98.22% |
| 4-(4-Fluorophenyl)benzoic acid |
|
|
|
|
|
|
|
|
|
|
|
99.01% |
| 4-Ethylphenyl sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
| 4-Ethylphenyl sulfate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| 4-Hydroxyresveratrol |
|
|
|
|
|
|
|
|
|
|
|
|
| 6,8-Diprenylorobol |
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| 6-Ethyl-7-hydroxy-4-methyl-2H-chromen-2-one |
|
|
|
|
|
|
|
|
|
|
|
|
| 8-O-Acetylharpagide |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| 8α-Tigloyloxyhirsutinolide 13-O-acetate |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| A-1155463 |
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| A-1155905 |
|
|
|
|
|
|
|
|
|
|
|
|
| A-1208746 |
|
|
|
|
|
|
|
|
|
|
|
|
| A-1210477 |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| A-1210477-piperazinyl |
|
|
|
|
|
|
|
|
|
|
|
|
| A-1211212 |
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| A-1248767 |
|
|
|
|
|
|
|
|
|
|
|
|
| A-1293102 |
|
|
|
|
|
|
|
|
|
|
|
|
| A-1331852 |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| A-371191 |
|
|
|
|
|
|
|
|
|
|
|
|
| A-385358 |
|
|
|
|
|
|
|
|
|
|
|
95.10% |
| A09-003 |
|
|
|
|
|
|
|
|
|
|
|
|
| A2AR/EGFR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| ABBV-167 |
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| ABBV-467 |
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| ABT-737 |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| AC-P19M |
|
|
|
|
|
|
|
|
|
|
|
|
| AF151 |
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| AKT1-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| Amantadine sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
| Amsacrine isethionate |
|
|
|
|
|
|
|
|
|
|
|
|
| Amsacrine lactate |
|
|
|
|
|
|
|
|
|
|
|
|
| AN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anhydrohirundigenin mono-thevetoside |
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Bcl-2 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD146 Antibody (AA98) |
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse 4-1BB/CD137 Antibody (3H3) |
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| anti-TNBC agent-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| anti-TNBC agent-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 201 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 296 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 304 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 306 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 310 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 43 |
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Anticancer agent 56 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 63 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 64 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 65 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antineoplaston A10 |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Antioxidant agent-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-217 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-55 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-77 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-78 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apogossypolone |
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Apoptosis inducer 19 |
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Apoptosis inducer 28 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 39 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 43 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 44 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 45 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 49 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 50 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 56 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 62 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptotic agent-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptotic agent-3 |
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| AS 1411 |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| AS 1411 sodium |
|
|
|
|
|
|
|
|
|
|
|
91.58% |
| AS 1411 sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
| Asaretoclax |
|
|
|
|
|
|
|
|
|
|
|
|
| Aspidin BB |
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Astin B |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Atiprimod |
|
|
|
|
|
|
|
|
|
|
|
|
| ATWLPPRAANLLMAAS |
|
|
|
|
|
|
|
|
|
|
|
|
| Avicin D |
|
|
|
|
|
|
|
|
|
|
|
|
| AVN-944 |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| AZ-PFKFB3-67 |
|
|
|
|
|
|
|
|
|
|
|
97.03% |
| AZD-5991 |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| AZD-5991 (S-enantiomer) |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| AZD-5991 Racemate |
|
|
|
|
|
|
|
|
|
|
|
|
| AZD4320 |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Azoramide |
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| BAD (103-127) (human) |
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| BAD (103-127) (human), FAM-labeled |
|
|
|
|
|
|
|
|
|
|
|
|
| BAD (103-127) (human), FAM-labeled TFA |
|
|
|
|
|
|
|
|
|
|
|
95.10% |
| Bad BH3 (mouse) |
|
|
|
|
|
|
|
|
|
|
|
|
| BAI1 |
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| BAI1 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Bak BH3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bak BH3 (72-87), TAMRA-labeled |
|
|
|
|
|
|
|
|
|
|
|
|
| BAK1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bak1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bak1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BAM7 |
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Barakol |
|
|
|
|
|
|
|
|
|
|
|
|
| Bax activator-1 |
|
|
|
|
|
|
|
|
|
|
|
98.45% |
| Bax activator-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bax agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| BAX Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bax inhibitor peptide V5 |
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| Bax inhibitor peptide, negative control |
|
|
|
|
|
|
|
|
|
|
|
|
| Bax Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BAX-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.05% |
| BBR-BODIPY |
|
|
|
|
|
|
|
|
|
|
|
98.15% |
| BChE-IN-49 |
|
|
|
|
|
|
|
|
|
|
|
|
| BcI-2/BcI-xI ligand 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2/Mcl-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2/Mcl-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2/Mcl-1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2/Mcl-1-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2/Mcl-1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-B inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Bcl-xL antagonist 2 |
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| BCL-xL ligand 2 |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL-xL ligand 3 |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL-xL ligand 4 |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL-xL ligand 6 |
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| BCL-XL-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL-XL-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2A1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2a1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2L1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2L10 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l10 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l10 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2L11 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l11 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l11 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL2L2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl2l2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| BCL6-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| BCL6-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| BCL6-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| BCL6-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| BDA-366 |
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| BDE30671203 |
|
|
|
|
|
|
|
|
|
|
|
|
| Beclanorsen |
|
|
|
|
|
|
|
|
|
|
|
|
| Beclanorsen sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Beclanorsen sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
| Beclin1-Bcl-2 interaction inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Benzylurea |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| BEPP hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| BFC1103 |
|
|
|
|
|
|
|
|
|
|
|
|
| BFC1108 |
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| Bfl-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bfl-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Bfl-1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bfl-1-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bfl-1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| Bfl-1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bfl-1-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| BH3I-1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| BI-3802 |
|
|
|
|
|
|
|
|
|
|
|
99.27% |
| Bid BH3 (80-99) |
|
|
|
|
|
|
|
|
|
|
|
|
| Bid BH3 (80-99) acetate |
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| Bid BH3 (80-99), FAM labeled |
|
|
|
|
|
|
|
|
|
|
|
|
| Bid BH3 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Bid BH3-Gly-r8 |
|
|
|
|
|
|
|
|
|
|
|
|
| BIHC |
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
| Bik BH3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bim BH3 |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Bim BH3, Peptide IV |
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Bim BH3, Peptide IV TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Bim-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| BM 957 |
|
|
|
|
|
|
|
|
|
|
|
|
| BM-1074 |
|
|
|
|
|
|
|
|
|
|
|
|
| BM-1197 |
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| BM-1244 |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| BM-962 |
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| BMS-195614 |
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| BPA-B9 |
|
|
|
|
|
|
|
|
|
|
|
98.50% |
| BPTQ |
|
|
|
|
|
|
|
|
|
|
|
|
| BRD-810 |
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| BRD-K20733377 |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| BRD-K44839765 |
|
|
|
|
|
|
|
|
|
|
|
|
| BRD-K56819078 |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| BRD1991 |
|
|
|
|
|
|
|
|
|
|
|
|
| BRD4 Inhibitor-15 |
|
|
|
|
|
|
|
|
|
|
|
|
| BRD4-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bruceantinol |
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| BT2 |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| BTSA1 |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Bufarenogin |
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Butyrolactone I |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| BW-AQ-113 |
|
|
|
|
|
|
|
|
|
|
|
|
| Bz 423 |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| c-MYC/BCL2 ligand 1 iodide |
|
|
|
|
|
|
|
|
|
|
|
|
| CA IX/VEGFR-2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| CAIX/CDK-2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Cajanol |
|
|
|
|
|
|
|
|
|
|
|
|
| Calactin |
|
|
|
|
|
|
|
|
|
|
|
|
| Calenduloside E |
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Candidone |
|
|
|
|
|
|
|
|
|
|
|
|
| Capeserod |
|
|
|
|
|
|
|
|
|
|
|
98.66% |
| Carbonic anhydrase-IN-35 |
|
|
|
|
|
|
|
|
|
|
|
|
| Cardanol monoene |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Carteolol |
|
|
|
|
|
|
|
|
|
|
|
|
| Caylin-2 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| CBI1 |
|
|
|
|
|
|
|
|
|
|
|
|
| CBI1 formic |
|
|
|
|
|
|
|
|
|
|
|
|
| CCT365386 |
|
|
|
|
|
|
|
|
|
|
|
|
| CCT369260 |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| CCT373566 |
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| CCT373567 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK1/2/4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK2-IN-49 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK4/6-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK9-IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK9-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK9-IN-47 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDKI-83 |
|
|
|
|
|
|
|
|
|
|
|
|
| Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) |
|
|
|
|
|
|
|
|
|
|
|
|
| CG-1521 |
|
|
|
|
|
|
|
|
|
|
|
95.71% |
| CG-3-246 |
|
|
|
|
|
|
|
|
|
|
|
|
| Ch282-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Chlorin e6 |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Chlorin e6 (solution) |
|
|
|
|
|
|
|
|
|
|
|
|
| CHNQD-01522 |
|
|
|
|
|
|
|
|
|
|
|
|
| Chuanbeinone |
|
|
|
|
|
|
|
|
|
|
|
|
| CID5721353 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Clausenidin |
|
|
|
|
|
|
|
|
|
|
|
|
| Clitocine |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| CLZ-8 |
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Copper tripeptide-3 |
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| COX-2-IN-59 |
|
|
|
|
|
|
|
|
|
|
|
|
| COX/5-LO-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| CPA-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Crispene E |
|
|
|
|
|
|
|
|
|
|
|
|
| Croconic acid disodium |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| CSN5-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| CT1-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| CT20p |
|
|
|
|
|
|
|
|
|
|
|
|
| CYD-2-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| CYD-2-88 |
|
|
|
|
|
|
|
|
|
|
|
|
| CYD-4-61 |
|
|
|
|
|
|
|
|
|
|
|
|
| Cytisine-platinum(IV) prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Cytochalasin H |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| D-Leucine amide-CDDO-Me-HMP |
|
|
|
|
|
|
|
|
|
|
|
|
| D-(+)-Phenyllactic acid |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Dalvotoclax |
|
|
|
|
|
|
|
|
|
|
|
|
| Daphnoretin |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Decyl gallate |
|
|
|
|
|
|
|
|
|
|
|
|
| DEG-77 |
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| Dehydrobruceine B |
|
|
|
|
|
|
|
|
|
|
|
|
| Dehydrocorydaline (hydroxyl) |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Deltamethrin-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Desmorpholinyl navitoclax-NH-Me |
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| Difopein |
|
|
|
|
|
|
|
|
|
|
|
|
| Difopein TFA |
|
|
|
|
|
|
|
|
|
|
|
95.35% |
| DIM-3,5-Cl2 |
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Dimebutic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Dimebutic acid-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Dimethyl bisphenolate |
|
|
|
|
|
|
|
|
|
|
|
|
| DL-erythro-Dihydrosphingosine |
|
|
|
|
|
|
|
|
|
|
|
98% |
| dMCL1-2 |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| DNH28 |
|
|
|
|
|
|
|
|
|
|
|
|
| DT2216 |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Dth |
|
|
|
|
|
|
|
|
|
|
|
|
| E722-2648 |
|
|
|
|
|
|
|
|
|
|
|
|
| E722-2648 TFA |
|
|
|
|
|
|
|
|
|
|
|
96.33% |
| Ecubectedin |
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Edelfosine |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| EGFR-IN-109 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-134 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-169 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-170 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-171 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-186 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-187 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-191 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-197 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-201 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/CDK2-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/HER2-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/HER2-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/VEGFR2-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/VEGFR2-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| eIF4E/eIF4G PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| EM20-25 |
|
|
|
|
|
|
|
|
|
|
|
|
| EMT inhibitor-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Entadamide A-CO-C12 |
|
|
|
|
|
|
|
|
|
|
|
|
| ERK5-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Estrogen receptor modulator 10 |
|
|
|
|
|
|
|
|
|
|
|
|
| F1324 |
|
|
|
|
|
|
|
|
|
|
|
|
| F1324 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| F1324 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| FCN-338 |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Ferroptosis/apoptosis inducer-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| FGFR-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
| FKA-9i |
|
|
|
|
|
|
|
|
|
|
|
|
| FLC-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Fluazinam |
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Flumethrin |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Flumethrin-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
| FMP |
|
|
|
|
|
|
|
|
|
|
|
|
| FPFS-1169 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| FS1 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| FuBIG |
|
|
|
|
|
|
|
|
|
|
|
|
| Furowanin A |
|
|
|
|
|
|
|
|
|
|
|
|
| FX1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| G-quadruplex ligand 4 |
|
|
|
|
|
|
|
|
|
|
|
|
| G721-0282 |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Ginkgo biloba extract |
|
|
|
|
|
|
|
|
|
|
|
|
| GL0388 |
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| Glufosfamide |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Glycocholic acid |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Glycocholic acid hydrate |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Glycocholic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| Glycocholic acid-13C2,d4N |
|
|
|
|
|
|
|
|
|
|
|
|
| Glycocholic acid-d4 |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| GM-90257 |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Gossypin |
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| Gossypol-13C2 |
|
|
|
|
|
|
|
|
|
|
|
|
| GPER/Bcl-2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| GQN-B37-E |
|
|
|
|
|
|
|
|
|
|
|
|
| GQN-B37-Me |
|
|
|
|
|
|
|
|
|
|
|
|
| HA14-1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Haplophytin-A |
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-51 |
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-91 |
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-93 |
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC6-IN-67 |
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC8-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
| Hexamethylene bisacetamide |
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| HK2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| hMcl-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Hrk BH3 |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| HSP70-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Hsp90-IN-42 |
|
|
|
|
|
|
|
|
|
|
|
|
| Humanin |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| IB001 |
|
|
|
|
|
|
|
|
|
|
|
|
| Icariside I |
|
|
|
|
|
|
|
|
|
|
|
98.76% |
| ICD inducer-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Icterogenin |
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1/TDO-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| IKKβ-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| IKKβ-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| IMB-XH1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| iMPZ-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| INH2BP |
|
|
|
|
|
|
|
|
|
|
|
|
| Isocryptotanshinone |
|
|
|
|
|
|
|
|
|
|
|
98% |
| Isolinderalactone |
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| JAK1/2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| JNJ-4355 |
|
|
|
|
|
|
|
|
|
|
|
|
| JS04 |
|
|
|
|
|
|
|
|
|
|
|
|
| Kanamycins sulfate |
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| Ki11502 |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| KRAS G12D-IN-37 |
|
|
|
|
|
|
|
|
|
|
|
|
| Kushenol Z |
|
|
|
|
|
|
|
|
|
|
|
|
| L-Azetidine-2-carboxylic acid |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| L-Selenocystine |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| L6H21 |
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Lacutoclax |
|
|
|
|
|
|
|
|
|
|
|
|
| Lisaftoclax |
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Lobetyol |
|
|
|
|
|
|
|
|
|
|
|
|
| Lometrexol disodium |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Longan cerebroside II |
|
|
|
|
|
|
|
|
|
|
|
|
| Lonitoclax |
|
|
|
|
|
|
|
|
|
|
|
|
| LSD1-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
| Lysosomal P-gp targeted agent 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| M24 |
|
|
|
|
|
|
|
|
|
|
|
|
| MA203 |
|
|
|
|
|
|
|
|
|
|
|
|
| MAPK-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| MAPK-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Maritoclax |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| MB725 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 10 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 12 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 13 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 14 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 15 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 16 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 17 |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Mcl-1 inhibitor 18 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 20 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 21 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 22 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 6 |
|
|
|
|
|
|
|
|
|
|
|
98.77% |
| Mcl-1 inhibitor 7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1 inhibitor 9 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-22 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
| MCL-1/BCL-2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.65% |
| MCL-1/BCL-2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| MCL-1/BCL-2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| MCL-1/BCL-2-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Mcl1 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| MCL1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Mcl1-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl1-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| Meayamycin B |
|
|
|
|
|
|
|
|
|
|
|
|
| Mesutoclax |
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| Methyl protodioscin |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| METTL3-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| Metuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
| MHY219 |
|
|
|
|
|
|
|
|
|
|
|
|
| MI-223 |
|
|
|
|
|
|
|
|
|
|
|
|
| MIK665 |
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| MIM1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Mito-fisetin mF7 |
|
|
|
|
|
|
|
|
|
|
|
|
| MK-2206 |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| MK-2206 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| MK-2206 free base |
|
|
|
|
|
|
|
|
|
|
|
|
| ML281 |
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| ML311 |
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| MLS-0053105 |
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| MLS-2384 free base |
|
|
|
|
|
|
|
|
|
|
|
|
| MM41 |
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| MN33-47 |
|
|
|
|
|
|
|
|
|
|
|
|
| MN33-63 |
|
|
|
|
|
|
|
|
|
|
|
|
| MNK1/2-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| MNK8 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Mol4 |
|
|
|
|
|
|
|
|
|
|
|
|
| MRT68921 |
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| MRT68921 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| MRT68921 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| MS1 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| MSN-125 |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| MSN-50 |
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| MST3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| MST3-IN-1 TFA |
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Multi-kinase-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Murizatoclax |
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Myrothecine A |
|
|
|
|
|
|
|
|
|
|
|
|
| n-Butyl-β-D-fructofuranoside |
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| N-Hydroxyphthalimide |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| N-Hydroxyphthalimide (Standard) |
|
|
|
|
|
|
|
|
|
|
|
98% |
| Navitoclax dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Navitoclax-piperazine |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| NEURL1B-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| NGI-189 |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| NKP608 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Nogo-B-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Nordentatin |
|
|
|
|
|
|
|
|
|
|
|
|
| NPB |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| NPS 2390 |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| NS-3-008 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| NSC 373981 |
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 850745 |
|
|
|
|
|
|
|
|
|
|
|
|
| NSC260594 |
|
|
|
|
|
|
|
|
|
|
|
97.50% |
| NSC666715 |
|
|
|
|
|
|
|
|
|
|
|
|
| NWP-0476 |
|
|
|
|
|
|
|
|
|
|
|
|
| Oblimersen |
|
|
|
|
|
|
|
|
|
|
|
|
| Oblimersen sodium |
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| Oblimersen sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
| OICR12694 |
|
|
|
|
|
|
|
|
|
|
|
|
| OICR12694 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Oxychlororaphine |
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| p38α inhibitor 6 |
|
|
|
|
|
|
|
|
|
|
|
|
| p53 DUBTAC modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| P53/TLR2 modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PARP1-IN-50 |
|
|
|
|
|
|
|
|
|
|
|
|
| PBX-7011 TFA |
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| PBX-7016 |
|
|
|
|
|
|
|
|
|
|
|
|
| PDE4B/D-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Pelcitoclax |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Phoyunbene B |
|
|
|
|
|
|
|
|
|
|
|
|
| Physcion 8-O-β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| PI-1840 |
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| PI3K-IN-58 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ/HDAC6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Pim-1 kinase inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Poly (I:C):Kanamycin (1:1) |
|
|
|
|
|
|
|
|
|
|
|
48.60% |
| Poly-L-lysine hydrobromide (MW 30000-70000) |
|
|
|
|
|
|
|
|
|
|
|
|
| Polyinosinic-polycytidylic acid |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Polyinosinic-polycytidylic acid (GMP Like) |
|
|
|
|
|
|
|
|
|
|
|
90.5% |
| PPIA-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
96.90% |
| PQ-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Prexigebersen |
|
|
|
|
|
|
|
|
|
|
|
|
| Procyanidin B2-3'-O-gallate |
|
|
|
|
|
|
|
|
|
|
|
|
| Propionyl-L-carnitine |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| PROTAC ATR degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC BcI-2/BcI-xI Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC Bcl-xL degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC Bcl-xL degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
98.23% |
| PROTAC Bcl-xL degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC Bcl-xL degrader-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC BCL-xL/BCL-w Degrader 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC Bcl2 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| PROTAC BRD4 Degrader-42 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC CB1R Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC EZH2 Degrader-44 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HDAC3 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC Mcl1 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| PROTAC PI3K/110β degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Protoapigenone |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| PRT543 |
|
|
|
|
|
|
|
|
|
|
|
|
| PTD10 |
|
|
|
|
|
|
|
|
|
|
|
97.38% |
| PUMA BH3 |
|
|
|
|
|
|
|
|
|
|
|
98.24% |
| PUMA BH3 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Pyridoclax |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| PZ-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| PZ671 |
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| PZ703b |
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| PZ703b hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| PZ703b TFA |
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| QNX-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| Quinalizarin |
|
|
|
|
|
|
|
|
|
|
|
97.23% |
| Quinpirole |
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| r8 Bid BH3 |
|
|
|
|
|
|
|
|
|
|
|
|
| rel-AZ5576 |
|
|
|
|
|
|
|
|
|
|
|
|
| ROR1-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| ROS-generating agent 1 |
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Rosomidnar |
|
|
|
|
|
|
|
|
|
|
|
|
| Rosomidnar sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Rosomidnar sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
| RPS6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| RU28362 |
|
|
|
|
|
|
|
|
|
|
|
|
| S-Petasin |
|
|
|
|
|
|
|
|
|
|
|
|
| S1g-10 |
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| S55746 |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| S55746 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| S63845 |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| S65487 |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| S65487 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| S65487 sulfate |
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Sabutoclax |
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| SACLAC |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Santamarine |
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| SC-2001 |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| SC-60 |
|
|
|
|
|
|
|
|
|
|
|
|
| Scoulerine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Selenocystine |
|
|
|
|
|
|
|
|
|
|
|
99% |
| Semaglutide (crude) |
|
|
|
|
|
|
|
|
|
|
|
77.53% |
| Semaglutide acetate |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Semaglutide sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Semaglutide, Cy5 labeled |
|
|
|
|
|
|
|
|
|
|
|
|
| Semaglutide-d8 tetraTFA |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| SF-9-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Shinpterocarpin |
|
|
|
|
|
|
|
|
|
|
|
|
| SHP2-D26 |
|
|
|
|
|
|
|
|
|
|
|
95.83% |
| SKLB70326 |
|
|
|
|
|
|
|
|
|
|
|
|
| SMBA1 |
|
|
|
|
|
|
|
|
|
|
|
99.5800% |
| Sonrotoclax |
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| SP-6-27 |
|
|
|
|
|
|
|
|
|
|
|
|
| Sphingosine |
|
|
|
|
|
|
|
|
|
|
|
|
| Spicamycin |
|
|
|
|
|
|
|
|
|
|
|
|
| ST09 |
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| STAT3-IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3-IN-46 |
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3-IN-51 |
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3/CAIX-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3/NF-κB-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Stellasterol |
|
|
|
|
|
|
|
|
|
|
|
|
| Stigmast-5-en-3-ol |
|
|
|
|
|
|
|
|
|
|
|
|
| SYM 2081 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Tambiciclib |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Tambiciclib dimaleate |
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Tambulin |
|
|
|
|
|
|
|
|
|
|
|
|
| Tapotoclax |
|
|
|
|
|
|
|
|
|
|
|
98.35% |
| Tau Protein Phosphorylation-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| TBC1D2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| TC11 |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| TCF4/β-catenin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| TCPOBOP |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Tegafur-gimeracil-oteracil potassium |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Tenacigenoside A |
|
|
|
|
|
|
|
|
|
|
|
|
| TFGF-18 |
|
|
|
|
|
|
|
|
|
|
|
|
| TFSeB |
|
|
|
|
|
|
|
|
|
|
|
|
| Thaspine acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| Theophylline-platinum(IV) prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Thevetiaflavone |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| TKL002 |
|
|
|
|
|
|
|
|
|
|
|
|
| TM-233 |
|
|
|
|
|
|
|
|
|
|
|
|
| TMX-2164 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topo I/DDX5-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topo I/II-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topo I/II-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I inhibitor 17 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I/II-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase II inhibitor 23 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase II/EGFR-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Torulene |
|
|
|
|
|
|
|
|
|
|
|
|
| TP-021 |
|
|
|
|
|
|
|
|
|
|
|
98.77% |
| Trijuganone C |
|
|
|
|
|
|
|
|
|
|
|
|
| TRP-601 |
|
|
|
|
|
|
|
|
|
|
|
|
| TS-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| TS-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-82 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-88 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin-IN-66 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin/LSD1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| TW-37 |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| TYMJ-01 |
|
|
|
|
|
|
|
|
|
|
|
|
| TZEP7 |
|
|
|
|
|
|
|
|
|
|
|
|
| UBX1325 |
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| UMI-77 |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| UMI-77-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Vacquinol-1 |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Vanillyl alcohol |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Vanillyl alcohol (Standard) |
|
|
|
|
|
|
|
|
|
|
|
98% |
| VEGFR-2-IN-36 |
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-62 |
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-70 |
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2/AKT-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR/PD-L1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Vicanicin |
|
|
|
|
|
|
|
|
|
|
|
|
| Vitexin B-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| VU0661013 |
|
|
|
|
|
|
|
|
|
|
|
98.45% |
| WEHI-3773 |
|
|
|
|
|
|
|
|
|
|
|
|
| WEHI-539 |
|
|
|
|
|
|
|
|
|
|
|
|
| WEHI-539 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| WH244 |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Withametelin B |
|
|
|
|
|
|
|
|
|
|
|
|
| WK499 |
|
|
|
|
|
|
|
|
|
|
|
|
| WR-S-462 |
|
|
|
|
|
|
|
|
|
|
|
|
| WX2-43 |
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| XAN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| XSJ151 |
|
|
|
|
|
|
|
|
|
|
|
|
| XSJ81 |
|
|
|
|
|
|
|
|
|
|
|
|
| XY221 |
|
|
|
|
|
|
|
|
|
|
|
|
| XYD049 |
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| XZ338 |
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| XZ739 |
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| YC137 |
|
|
|
|
|
|
|
|
|
|
|
|
| YCW-E11 |
|
|
|
|
|
|
|
|
|
|
|
|
| YVPGP |
|
|
|
|
|
|
|
|
|
|
|
|
| YX0798 |
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| Zamzetoclax |
|
|
|
|
|
|
|
|
|
|
|
|
| Zenidolol |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| ZLMT-72 |
|
|
|
|
|
|
|
|
|
|
|
|
| ZM484 |
|
|
|
|
|
|
|
|
|
|
|
|
| ZSNI-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| α-D-Glucosyl hesperidin |
|
|
|
|
|
|
|
|
|
|
|
|
| α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu |
|
|
|
|
|
|
|
|
|
|
|
|
| β,β-Dimethylacrylshikonin |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| β-Carotene-15,15'-epoxide |
|
|
|
|
|
|
|
|
|
|
|
|
| β-Eleostearic acid |
|
|
|
|
|
|
|
|
|
|
|
|
| Beta-Sitosterol (purity>98%) |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Triclabendazole |
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Proquinazid |
|
|
|
|
|
|
|
|
|
|
|
|
| Hexane-2,5-dione |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Eurycomalactone |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Sericin |
|
|
|
|
|
|
|
|
|
|
|
0% |
| Salvianolic acid D |
|
|
|
|
|
|
|
|
|
|
|
95.15% |
| Salvianolic acid F |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Sodium glycocholate hydrate, 98% |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Dihydroactinidiolide |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Dihydrocapsaicin-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrocapsaicin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Diallyl Trisulfide |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Pendimethalin |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Sodium Selenite |
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Ginsenoside Rh4 |
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ciwujianoside B |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Azadirachtin |
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Co(III) protoporphyrin IX chloride |
|
|
|
|
|
|
|
|
|
|
|
95% |
| Desacetylcinobufotalin |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Bicyclol |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| trans-Vaccenic acid |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| trans-Vaccenic acid-d13 |
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-Ferulic acid |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| (E)-Ferulic acid-d3 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Semaglutide-d8 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Pyraclostrobin-d6 |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Pyraclostrobin |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Caudatin |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Methyl caffeate |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Digitoxin |
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Rehmannioside A |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Rehmannioside D |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Rhein 8-O-β-D-Glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Obatoclax |
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| Obatoclax Mesylate |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Hawthorn Extract |
|
|
|
|
|
|
|
|
|
|
|
|
| Levonorgestrel |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Gymnoside II |
|
|
|
|
|
|
|
|
|
|
|
|
| Ascorbyl palmitate |
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Secoxyloganin |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Taccalonolide A |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Gossypol |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Jaceosidin |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Jaceosidin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| Hesperetin |
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| 13-Oxyingenol-13-dodecanoate |
|
|
|
|
|
|
|
|
|
|
|
95.73% |
| Flurochloridone |
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Chlorphoxim |
|
|
|
|
|
|
|
|
|
|
|
|
| Lometrexol |
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Lometrexol hydrate |
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Deltamethrin |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Macranthoside B |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Griseofulvin |
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Ganoderma Lucidum/Reishi Extract |
|
|
|
|
|
|
|
|
|
|
|
41.20% |
| Daphnetin |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Polygalasaponin F |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Glycocholic acid-d5 |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Kansuinine A |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Navitoclax |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Navitoclax-d8 |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Thiophanate-Methyl |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Sorafenib tosylate |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Chelerythrine-d6 chloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Chelerythrine |
|
|
|
|
|
|
|
|
|
|
|
|
| Proadifen hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Chelerythrine chloride |
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Dehydrocorydaline chloride |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Amantadine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Dehydrocorydaline nitrate |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Hypocrellin A |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Araloside A |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Bromuconazole |
|
|
|
|
|
|
|
|
|
|
|
|
| Sorafenib |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Semaglutide |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Semaglutide-13C6,15N TFA |
|
|
|
|
|
|
|
|
|
|
|
96.04% |
| Semaglutide TFA |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Corynoline |
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Lobaplatin |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Venetoclax |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Venetoclax-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Venetoclax-d8 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Grosvenorine |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Carboxymethyl chitosan |
|
|
|
|
|
|
|
|
|
|
|
90% |
| Dehydrocorydaline |
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| Sotetsuflavone |
|
|
|
|
|
|
|
|
|
|
|
|
| Benzbromarone |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Estradiol benzoate |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Stem bromelain |
|
|
|
|
|
|
|
|
|
|
|
|
| Sulforaphane |
|
|
|
|
|
|
|
|
|
|
|
99.01% |
| Lariciresinol |
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Puerarin 6''-O-Xyloside |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Gambogic Acid |
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| Dimebutic acid |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Simazine-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
| Simazine |
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| (+)-Apogossypol |
|
|
|
|
|
|
|
|
|
|
|
|
| Glutamic acid sodium salt |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Cardamonin |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Peiminine |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Coenzyme Q0 |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Damulin B |
|
|
|
|
|
|
|
|
|
|
|
|
| Gossypol (acetic acid) |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Paris saponin VII |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Amantadine |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Amantadine-d6 |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Scoulerine |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Koumine |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Continentalic acid |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Nivalenol |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Nivalenol-13C15 |
|
|
|
|
|
|
|
|
|
|
|
|
| Triptophenolide |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Triptophenolide (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| Fezakinumab |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Dihydrokaempferol |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Verbenalin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Flavokawain B |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Aflatoxin B1 |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Diosbulbin B |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Destruxin B |
|
|
|
|
|
|
|
|
|
|
|
99.35% |